Cholesterol-lowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patients.
In a randomized design study in 66 hypercholesterolemic patients, dosages of 10 g of colestipol HCl twice daily lowered serum cholesterol an average of 19% more than placebo therapy. These results are comparable to those in other studies in which the same total daily dose was given in three or four doses. The most common side effect was constipation, reported by 6 patients on colestipol HCl and 3 patients on placebo. No untoward systemic reactions or abnormal laboratory data were seen except for a slight rise in serum alkaline phosphatase during colestipol HCl therapy. The drug was well accepted by most patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000924:Anticholesteremic Agents; D002784:Cholesterol / Q000009:adverse effects / Q000097:blood; D002986:Clinical Trials as Topic; D003084:Colestipol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011073:Polyamines / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D011073:Polyamines; D002784:Cholesterol; D000469:Alkaline Phosphatase; D003084:Colestipol